key: cord-0780785-bmbc238n authors: Westerhuis, B. M.; de Bruin, E.; Chandler, F. D.; Ramakers, C. R. B.; Okba, N. M. A.; Li, W.; Goossens, H.; de Jong, M. D.; Bosch, B. J.; Haagmans, B. L.; Fraaij, P. L.; Sikkema, R. S.; Koopmans, M. P. G. title: Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands date: 2020-08-24 journal: nan DOI: 10.1101/2020.08.21.20177857 sha: bd18ffe7851f95d222fcc83afb918319675638fe doc_id: 780785 cord_uid: bmbc238n Understanding the coronavirus (CoV) antibody landscape in relation to disease and susceptibility is critical for modelling of steps in the next phase during the current covid-19 pandemic. In March 2020, during the first month of the epidemic in The Netherlands, we performed cross sectional studies at two time points amongst patients of the Erasmus Medical Centre in Rotterdam, to assess the presence of antibodies against seasonal human coronaviruses (OC43, 229E, NL63, HKU1), emerging zoonotic coronaviruses (SARS, MERS) and SARS-CoV-2 in nine different age groups. We observed minimal SARS-CoV-2 reactivity early March (0.7% of sera), increasing to 3.0%, four weeks later, suggesting probably undetected cases during this early phase of the epidemic. Antibody responses were mostly coronavirus species specific at young age, but possible cross-reactivity between human seasonal CoVs was observed with increasing age. interval between both sampling moments, a clear rise in SARS-CoV-2 seropositivity was 65 observed. The prevalence of antibodies to any of the SARS-CoV-2 antigens increased from 66 0.7% (6/ 879) at T1 to 3.0% (22/729) at T2. When only taking into account plasma samples 67 testing positive for all three antigens, the prevalence was 0.1% (1/879) at T1 and 2.3% (17/729) 68 at T2. Most antibody positive sera were detected in age groups 40-60 and 60-80. None of the 69 children below five years of age were seropositive (Tabel 1). 70 71 72 In sera with SARS-CoV-2 responses, crossreactivity was shown against the SARS and MERS 73 antigens ( Figure 2 ). The majority of antibodies binding to antigens from seasonal human 74 coronaviruses were present from an early age onwards in most plasma samples, although 75 differences in antibody responses were detected between coronaviruses and between antigens 76 from the same virus ( Figure 2) . The median fluorescence level of hCoV antibody reactivity was 77 lowest in 6-24 month old children and increased from age groups 2-5 years old to >20 years old, 78 depending on the antigen. For some antigens a slight decrease in binding antibodies was 79 observed in individuals above 80 years old. 80 To determine how reactivity of the different seasonal hCoV antibody titers correlate with 82 (multiple) infections during lifetime, endpoint titers were calculated for all hCoV antigens for age 83 groups 0-2y (n=36 samples), 2-10y (n=38), 10-40y (n=37), 40+ (n=58) and 60+ (n=39). When 84 looking at all data combined, highest correlations were observed between S1 and the S 85 ectodomain from the same virus, and within alpha and beta coronaviruses, respectively. When 86 breaking the groups down in age groups, mainly strain specific signals were observed in the 87 lowest age group, with broadening of the correlation of antibody titers within the alpha and the 88 betacoronaviruses between the ages of 2 and 40 years, and further broadening of responses 89 between alpha and betacoronaviruses in individuals of 60 years and older ( Figure 3) . 90 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 24, 2020 . . https://doi.org/10.1101 /2020 Serological assays have been shown to be of great value in population surveys of viral 92 infections additional to virus detection assays. In this study we used a multiplex serological 93 protein microarray to detect possible infections of SARS-CoV-2 early in the epidemic among the 94 general population, including children and adolescents, as well as age stratified serological 95 responses against a broad range of other CoV strains. The seropositivity at 4 weeks after 96 confirmation of the first cases of SARS-CoV-2 in our study population revealed early, probably 97 undetected, cases during this period, confirming the importance of adding serosurveys to 98 assess the extent of spread of COVID-19. The highest seroprevalence was detected in the 99 group 40 years and older. 100 Our data are in agreement with results of screening among human blood donors between 1-15 102 April, showing an average seroprevalence of 2.7% country wide, up to 9.5% in the hardest-hit 103 areas (2). Worldwide most early seroprevalence studies showed similar numbers ranging from 104 0.4 -14% (3), although seroprevalence can be considerably higher among outbreak settings (4, 105 5). Results of serological testing in a low prevalence situation need to be interpreted with 106 caution, as low-level cross-reactivity has been observed for most currently available assays (6). 107 A good practice can be to use combined assay results, counting only samples that had antibody 108 reactivity to two or three of the SARS-CoV-2 antigens as positives (7). By using this criterion, 109 and the high stringency cut-off defined by ROC analysis including serum samples form persons 110 with recent seasonal coronavirus infections, we trust that our estimates are robust. 111 The use of leftover specimens across age ranges does provide a broader picture of community 113 circulation than can be obtained with blood donors. The lack of SARS-CoV-2 antibody positive 114 children below five years of age may be explained by lower infection rates or susceptibility in 115 younger age groups, a lower proportion of severe cases, or both (8-10). We therefore were 116 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 24, 2020 . . https://doi.org/10.1101 /2020 interested to assess whether the lack of SARS-CoV-2 infections was potentially related to 117 immunity from other coronavirus infections. 118 The four endemic hCoVs (229E, NL63, OC43, and HKU) account for about 10% of all upper 120 respiratory tract infections in adults (11, 12), but most CoV cases among healthcare seeking 121 individuals with respiratory symptoms are detected in children <5 years old and elderly >64. In a 122 limited number of clinical case series in Europe, OC43 and NL63 were most commonly 123 detected, while HKU1 and 229E appear more infrequently or even in a temporal pattern (11, 13, 124 14) . In our study, the prevalence and the magnitude of antibody positive signals increased from 125 two years of age, although at a different rate for the different viruses. The antibodies were 126 mostly specific for the different human CoVs in the younger age group, with limited correlation 127 between signals for antigens from different human seasonal coronaviruses belonging to the 128 same genera. Therefore, we find no evidence for presence of cross-reactive antibodies as an 129 explanation for the seemingly lower rate of SARS-CoV-2 infections in children. 130 131 This pattern changed with increasing age, with increasing correlation between antibody signals 132 for viruses within the same hCoV in adults, and even across hCoVs in older individuals. Cross 133 reactivity of antibodies between seasonal coronaviruses and SARS have been described in the 134 past. During an OC43 outbreak in British Colombia in 2003, cross-reactive antibodies to the 135 SARS-CoV nucleocapsid protein have been shown (15) and a recent study showed very limited 136 cross-reactivity with the SARS-CoV-2 ectodomain and S2 antigens in a naïve population, but 137 not with the other SARS-CoV antigens (RBD, S1 and NP) (16). Our assay cut-off was set for 138 high specificity of the SARS-CoV-2 measurements and therefore low-level binding would not be 139 detected. However, we did observe cross-reactive antibodies to MERS-CoV S ectodomain and 140 nucleocapsid antigens, without detectable responses to SARS-CoV-2, especially with increasing 141 age. The possible broadening of anti S1 and S ectodomain antibodies with increasing age 142 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20177857 doi: medRxiv preprint raises questions about the functionality of cross-reactive antibodies, although cross reaction 143 with SARS-CoV-2 was not detected. 144 The methods we used have inherent disadvantages. In agreement with the general data 146 protection regulation samples were collected in an anonymous manner, and as a consequence 147 patients may have been included more than once. In addition, while the use of leftover serum 148 collections is a proven method for fast deployment of sero-surveys, the study was hampered by 149 the fact that during the first wave of the COVID-19 pandemic non-essential hospital visits were 150 downscaled and individuals with mild respiratory disease strongly discouraged to visit health 151 care providers. This especially affected hospital visits in the pediatric population as also 152 reflected in our study with low numbers of serum samples for the pediatric population obtained 153 on time point 2. It may therefore be that individuals with mild symptoms avoided the hospital and 154 thus our study may underestimate the true sero-incidence in catchment area. 155 156 Nonetheless, we present an overview of the coronavirus antibody landscape in persons across 157 all age groups, and show specific responses to SARS-CoV-2 in the same multiplex assay 158 format. The presence of possible cross-hCoV and cross-subgroup binding antibodies with 159 increasing age warrants further study in relation to disease outcomes. by Public Health England as a pragmatic approach to gathering essential baseline data for 166 population exposure assessment during a rapidly evolving epidemic (17). Leftover lithium-167 heparin plasma samples submitted for general 24/7 clinical chemistry analyses at the Erasmus 168 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20177857 doi: medRxiv preprint medical center were collected. Samples from patients in which a SARS-CoV-2 PCR was 169 performed were excluded regardless of the result. Collection of plasma samples was done over 170 a 5 days period at 2 time points, March 2nd and April 3rd. To allow for additional or repeat 171 testing of archived samples if required clinically, left-over samples were retrieved after 4 to 7 172 days of cold storage (4C). The majority of samples from the children's cohort (<18 years) were 173 collected through finger or heel stick (capillary blood). The vast majority of blood from the adult 174 age cohorts were collected via venepuncture (venous blood). Only information regarding the 175 age was collected from the sera, covering nine age groups ( Table 1) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20177857 doi: medRxiv preprint Recombinant proteins were printed using a non-contact printer (sciFlexarrayer SX, Scienion, 196 Germany) on glass microscope slides coated with 64 pads of nitrocellulose creating 64 protein 197 arrays per slide which were used to measure binding antibodies present in serum, as described 198 before (19). Briefly, serum was diluted 1 in 20 in Blotto blocking buffer (Thermo Fisher Scientific 199 Inc., Rockford, USA) containing 0,1 percent Surfact Amps (Thermo Fisher Scientific Inc. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 24, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 24, 2020. . S ecto NP S1 S ecto NP S1 S ecto NP S1 S ecto NP S1 S ecto NP A B C D E F median fluorescence -background . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 24, 2020. . Figure 2 ; Fluorescence signals against CoV antigens. Sera with fluorescence signals above the cutoff against SARS-CoV-2 S1 and S-ecto and SARS-CoV NP are indicated in red. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 24, 2020. . Figure 3 ; Pearson correlation heatmaps of binding antibody titers to HKU1, OC43, NL63 and 229E S1 and ectodomains . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 24, 2020 . . https://doi.org/10.1101 /2020 S 1 t i m e p o i n t 1 t i m e p o i n t 2 t o t a l p o s i t i v e p e r c e n t a g e t o t a l p o s i t i v e p e r c e n t a g e 6 -1 2 m o n t h s 4 1 0 0 , 0 1 7 0 0 , 0 1 -2 y e a r s 7 5 0 0 , 0 1 4 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20177857 doi: medRxiv preprint 5 -1 0 y e a r s 9 6 0 , 0 3 4 0 , 0 1 0 -2 0 y e a r s 1 3 1 0 , 0 1 3 9 1 0 , 7 2 0 -4 0 y e a r s 1 3 1 0 , 0 1 4 0 2 1 , 4 4 0 -6 0 y e a r s 1 3 4 1 0 , 7 1 4 0 5 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 24, 2020. . https://doi.org/10.1101/2020.08.21.20177857 doi: medRxiv preprint RS and MK wrote the manuscript and executed the analyses, FC executed the 223